FDA approves Imbruvica to treat chronic lymphocytic leukemia

Author(s):

On Feb. 13, the U.S. Food and Drug Administration (FDA) expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia patients who have received at least one previous therapy.
Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here